Biotech firm Mylab Discovery Solutions partnered with US-based medical diagnostic device company Called Hemex Health to develop wearable diagnostic solutions for point-of-care (POC) testing of novel coronavirus and other diseases. .
The collaboration aims to increase testing capabilities for Covid-19 around the world. The companies expect the first product of this technology partnership to launch in November 2021.
After the second wave, decentralized testing had become important due to the limited capacity of traditional laboratories. The portable diagnostic and testing device enables testing anywhere, in a wide range of environmental conditions, and without the need to transport the sample, enabling fast results for patients.
Mylab, backed by Adar Poonawalla of the Serum Institute of India, is dedicated to diagnostic solutions, including the country’s first Covid-19 test kit and self-test kits for Covid-19. Hasmukh Rawal, MD, Mylab Discovery Solutions, said: “Hemex had experience developing portable POC diagnostic machines that would be combined with Mylab’s Fluorescence Immunoassay (FIA) test kits to make testing available anywhere. place. The diagnostic solution will be jointly introduced in international markets, including the United States, Europe and Asia. “
According to the technology association, Mylab would develop test trials and Hemex would provide its Gazelle POC test platform and expertise. They will work on FIA and electrophoresis-based diagnostic tests that are more sensitive than rapid normal antigen tests and have fewer false negatives, Mylab said.
Patti White, CEO and co-founder of Hemex Health, said the partnership with Mylab would provide groundbreaking new tests for Covid-19 and other diseases in the future. Hemex Health is supported by TiE Global Angels and the Cleveland Clinic. It has distributed a point-of-care sickle cell test on its Gazelle diagnostic device in nine countries.